This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Small-Caps Surge Up to 1,640% in a Year

5. Global Axcess (GAXC), an owner of 4,500 ATMs and DVD kiosks in the U.S., returned 514% over the past year. Global Axcess hasn't yet "broken the buck" and is currently trading over-the-counter at around 89 cents a share, with a market value of $19 million. During the past three years, Global Axcess has increased profit 31% annually, on average. Considering that growth rate, the stock appears undervalued at a price-to-earnings ratio of 11.

4. Culp (CFI - Get Report), a maker of mattress and upholstery fabrics, ascended 563% during the past year. Culp endured a difficult fiscal 2009, posting losses in its second and third quarters, but then mounted a successful turnaround. It swung to a fiscal second-quarter profit of $2.9 million, or 22 cents a share, from a loss of $41 million, or $3.23, a year earlier. The company's operating margin widened from 3.7% to 7.6%.

3. High-tech-equipment maker Veeco Instruments (VECO - Get Report) climbed 578% in the past 12 months. Veeco designs equipment used by the data storage, semiconductor and wireless industries. It suffered losses in the first half of 2009, but resumed profitability in the third and fourth quarters. The company possesses a liquid balance sheet, with $284 million of cash and $101 million of debt.

2. Biotech darling Dendreon (DNDN) soared 726% during the past year as investors placed bets on prostate cancer drug Provenge. Dendreon is consistently unprofitable, but Provenge is in the final stage of Food and Drug Administration approval, with a notification deadline of May 1. If the drug meets criteria, Dendreon plans to commercialize independently in the U.S. It's considering overseas partnerships.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
VCI $0.00 0.00%
HDII $0.01 0.00%
CFI $26.18 0.61%
DNDN $0.06 -6.02%
VECO $29.91 1.10%

Markets

DOW 18,092.98 +68.92 0.38%
S&P 500 2,117.61 +9.32 0.44%
NASDAQ 5,031.8070 +26.4160 0.53%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs